Document/ExhibitDescriptionPagesSize 1: 8-K Current Report HTML 34K
2: EX-99.1 Miscellaneous Exhibit HTML 13K
6: R1 Cover HTML 47K
9: XML IDEA XML File -- Filing Summary XML 11K
7: XML XBRL Instance -- kprx-20230207_htm XML 22K
8: EXCEL IDEA Workbook of Financial Reports XLSX 8K
4: EX-101.LAB XBRL Labels -- kprx-20230207_lab XML 69K
5: EX-101.PRE XBRL Presentations -- kprx-20230207_pre XML 34K
3: EX-101.SCH XBRL Schema -- kprx-20230207 XSD 10K
10: JSON XBRL Instance as JSON Data -- MetaLinks 12± 17K
11: ZIP XBRL Zipped Folder -- 0001372514-23-000010-xbrl Zip 19K
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class:
Trading Symbol(s)
Name of each exchange on which registered:
iCommon Stock, $0.01 par value
iKPRX
iNASDAQ
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 8.01. Other Events.
On February 7, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release
announcing that it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis or other autoimmune diseases (OPRA+). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned thereunto duly authorized.